Hurley Capital LLC Makes New Investment in Penumbra, Inc. (NYSE:PEN)

Hurley Capital LLC acquired a new stake in Penumbra, Inc. (NYSE:PEN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 230 shares of the company’s stock, valued at approximately $56,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. UMB Bank n.a. lifted its position in Penumbra by 57.4% in the fourth quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $46,000 after buying an additional 70 shares during the last quarter. Huntington National Bank lifted its holdings in shares of Penumbra by 138.7% in the 4th quarter. Huntington National Bank now owns 265 shares of the company’s stock worth $63,000 after acquiring an additional 154 shares during the last quarter. Mather Group LLC. grew its holdings in Penumbra by 208.0% during the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock valued at $73,000 after purchasing an additional 208 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Penumbra by 25.0% during the 4th quarter. Jones Financial Companies Lllp now owns 375 shares of the company’s stock valued at $89,000 after purchasing an additional 75 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Penumbra by 160.8% in the 4th quarter. GAMMA Investing LLC now owns 446 shares of the company’s stock worth $106,000 after purchasing an additional 275 shares during the period. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Penumbra Stock Performance

Shares of Penumbra stock opened at $262.37 on Friday. Penumbra, Inc. has a one year low of $148.00 and a one year high of $310.00. The company has a market capitalization of $10.11 billion, a PE ratio of 771.66, a P/E/G ratio of 2.83 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The company has a 50-day simple moving average of $274.48 and a two-hundred day simple moving average of $245.61.

Penumbra (NYSE:PEN) last announced its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.09. The company had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. Research analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Thomas Wilder sold 360 shares of the business’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $264.58, for a total transaction of $95,248.80. Following the sale, the director now owns 4,533 shares in the company, valued at approximately $1,199,341.14. The trade was a 7.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Lambert Shiu sold 501 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $282.88, for a total transaction of $141,722.88. Following the completion of the transaction, the chief accounting officer now directly owns 32,969 shares of the company’s stock, valued at $9,326,270.72. The trade was a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 111,236 shares of company stock worth $31,222,390 in the last ninety days. 5.00% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Bank of America initiated coverage on Penumbra in a research note on Friday, March 14th. They set a “buy” rating and a $320.00 target price on the stock. Citigroup increased their target price on Penumbra from $220.00 to $245.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group boosted their target price on shares of Penumbra from $323.00 to $340.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Wells Fargo & Company raised their price target on shares of Penumbra from $275.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Finally, Royal Bank of Canada boosted their price objective on shares of Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a research report on Wednesday, February 19th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $294.47.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.